ReachRxResearch
Home
Research
Sign Up
Short‐Course Subcutaneous Immunotherapy With Mannan‐Conjugated Birch Pollen Allergoids: Consistent Clinical and Immunological Improvements
Back to Research Hub
  1. Home
  2. Research Hub
  3. Short‐Course Subcutaneous Immunotherapy…

Short‐Course Subcutaneous Immunotherapy With Mannan‐Conjugated Birch Pollen Allergoids: Consistent Clinical and Immunological Improvements

Clinical and Translational Allergy·October 4Open Access
AllergyConfirms priorAllergic RhinoconjunctivitisRandomized Controlled TrialMannan-Conjugated AllergoidSubcutaneous Allergen ImmunotherapyMixedEP-088 T502 Mannan-Conjugated Birch Pollen Allergoid

Summary

View source

What was studied

This confirmatory double-blind, placebo-controlled phase III trial evaluated the efficacy, safety, tolerability, and immunological effects of short-course pre-seasonal subcutaneous immunotherapy with mannan-conjugated birch pollen allergoid EP-088_T502 (cumulative dose 28,000 mTU over 8 injections across 6 visits) versus placebo in 278 adults and adolescents with birch pollen-induced allergic rhinoconjunctivitis during the 2025 birch pollen season.

Key findings

EP-088_T502 significantly reduced the combined symptom and medication score (CSMS) during peak pollen season versus placebo (mean absolute difference −0.31, 95% CI −0.56 to −0.05; p = 0.0169; ~18% median reduction); health-related QoL improved by 20% (p < 0.005); Bet v 1-specific IgG4 rose 6.4-fold versus placebo (p < 0.0001); and the IgE/IgG4 ratio fell 73% from baseline and 69% versus placebo (both p < 0.0001).

Study limitations

The standardised effect size (0.31) fell below the proposed minimally clinically important difference threshold of 0.5 in the primary FAS analysis; the adolescent subgroup was very small (n = 13, only 4.7% of participants), limiting any conclusions for that age group; and pollen-count data from several monitoring stations were incomplete, requiring a sensitivity analysis using weather service forecast data.

Clinical implications

A short 6-visit pre-seasonal SCIT course with EP-088_T502 at 28,000 mTU meaningfully reduces birch pollen allergy symptoms and medication use with a strong IgG4 immunological response, but clinicians should note that one grade III systemic reaction occurred (in 5.9% of active-treated participants overall), underscoring the need for standard SCIT safety precautions including 30-minute post-injection observation.

Caveats

  • Multiple secondary and exploratory p-values were not adjusted for multiple comparisons, increasing the risk of false-positive secondary findings
  • One grade III systemic allergic reaction (considered treatment-related) occurred among 186 active-treated participants; clinicians must have emergency management protocols in place for all SCIT administrations
  • The adolescent subgroup (n=13) was too small for reliable conclusions; findings in that group are exploratory only
Show all 4
  • The primary CSMS effect size (0.31) was below the proposed minimally clinically important difference threshold of 0.5; clinical significance of the benefit should be interpreted cautiously

Related Questions

Explore related topics

Short-course pre-seasonal subcutaneous immunotherapy for birch pollen allergic rhinoconjunctivitis efficacy and safetyMannan-conjugated allergoid SCIT immunological response IgG4 birch pollenCombined symptom and medication score outcomes in allergen immunotherapy clinical trials

Publication Details

Year
2026
Journal
Clinical and Translational Allergy
Sample Size
n=278
Source
View article
Keep scrolling
More content below.
Up Next